Physician profile
Ban Q Vu
NPI 1043261936
$16,501.67
in general payments reported to CMS, 2019-2025
35 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,351 · 2020: $1,098 · 2021: $1,310 · 2022: $467 · 2023: $3,051 · 2024: $2,931 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,275 · Travel and Lodging: $1.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,274.70 |
| Travel and Lodging | $1.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,305.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $1,808.54 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $1,805.84 | 2019-2025 | Jardiance, Taltz |
| Astrazeneca Pharmaceuticals LP | $1,602.17 | 2019-2023 | Farxiga, Lokelma, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,056.77 | 2019-2023 | Jardiance |
| Abbvie INC. | $793.04 | 2019-2024 | Qulipta, Ubrelvy |
| Phathom Pharmaceuticals, INC. | $742.47 | 2024-2025 | Voquezna |
| Abbott Laboratories | $418.29 | 2023-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Glaxosmithkline, LLC. | $365.75 | 2024-2025 | Arexvy |
| Intercept Pharmaceuticals, INC. | $358.98 | 2019-2023 | Ocaliva |
| Janssen Pharmaceuticals, INC | $310.12 | 2019 | |
| Insulet Corporation | $290.02 | 2023-2025 | Omnipod |
| Scilex Pharmaceuticals INC. | $277.16 | 2024 | |
| Galderma Laboratories, L.P. | $269.09 | 2025 | Nemluvio |
| Redhill Biopharma INC. | $260.18 | 2024-2025 | Talicia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $244.86 | 2019 | |
| Leo Pharma INC. | $242.77 | 2024-2025 | Adbry |
| Novo Nordisk INC | $240.03 | 2020-2021 | |
| Corcept Therapeutics | $227.43 | 2023-2024 | Korlym |
| Amarin Pharma, INC. | $210.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.53 | 2019 | |
| Genzyme Corporation | $171.73 | 2025 | |
| Abiomed | $137.41 | 2025 | |
| Celgene Corporation | $134.04 | 2019 | |
| Theratechnologies INC. | $125.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Ardelyx, INC. | $125.00 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $125.00 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $116.24 | 2021 | |
| Inari Medical, INC. | $92.78 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ucb, INC. | $79.22 | 2021 | |
| Covidien LP | $74.26 | 2019 | |
| Dexcom, INC. | $40.97 | 2025 | Dexcom G6 Transmitter |
| Orthofix Medical, INC. | $4.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ban Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.